Artios Pharma closed a $115 million financing to accelerate clinical programs targeting DNA damage response pathways, building on the company’s strategy of exploiting tumor DNA‑repair dependencies similar to PARP inhibition. The Series D will support mid‑stage studies of Artios’ lead candidates and broaden biomarker efforts to define responsive patient populations. Company statements positioned the raise as runway extension for multiple clinical readouts and to expand combination strategies, while investors cited the attractive therapeutic rationale for DDR targeting. The financing reflects continued capital flow into oncology platforms with validated mechanistic hooks.